Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Brand Name :
Nubian
Synonyms :
Nalbuphin, nalbufina
Class :
opioids
Dosage Forms & StrengthsÂ
Injectable solutionÂ
10mg/mlÂ
20mg/mlÂ
Patients tolerant to opioids:
ÂĽ dose of 10-20mg/70 kg SC/IV/IM should be administered every 3-6
hours. Do not exceed 160mg/day
Non-tolerant patients to opioids
10-20mg/70 kg SC/IV/IM should be administered every 3-6 hours when necessary
Do not exceed 20 mg/individual dose
0.3 - 3.0
mg/kg
Solution
Intravenous (IV)
for 10-15 mins
then 0.25-0.5mg/kg when necessary
Dosage Forms & StrengthsÂ
Injectable solutionÂ
10mg/mlÂ
20mg/mlÂ
<1 year: Safety and efficacy not established
>1 year:0.1-0.2mg/kg SC/IV/IM should be administered every 3-4 hours when necessary
Do not exceed 160mg/day
may increase the effect of opioid agonists
may increase the CNS depressant effect
may increase the depressant effect of opioid agonists
may increase the depressant effect of opioid agonists
may increase the depressant effect of opioid agonists
may increase the depressant effect of opioid agonists
may increase the depressant effect of opioid agonists
may increase the CNS depressant effect
may increase the CNS depressant effect
may decrease the therapeutic effect of opioids
may increase the constipation effect of opioid agonist
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the analgesic effect of opioid agonists
may increase the toxic effects of opioid agonists
may increase the toxic effects of opioid agonists
may increase the toxic effects of opioid agonists
may increase the toxic effects of opioid agonists
may increase the toxic effects of opioid agonists
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the toxic effects of diuretics
may increase the toxic effects of diuretics
may increase the toxic effects of diuretics
may increase the toxic effects of diuretics
may increase the toxic effects of diuretics
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may decrease the therapeutic activity of opioid agonists
may increase the CNS depressant effect
may increase the sedative effect of CNS depressants
may increase the sedative effect of CNS depressants
Frequency defined:Â Â
>10%Â
SedationÂ
1-10%Â
DizzinessÂ
HeadacheÂ
XerostomiaÂ
NauseaÂ
VomitingÂ
<1%Â
BradycardiaÂ
DyspneaÂ
HypotensionÂ
MiosisÂ
Respiratory depressionÂ
UrticariaÂ
BurningÂ
Pulmonary edemaÂ
TachycardiaÂ
vertigoÂ
Pregnancy consideration: Not recommended during pregnancyÂ
Lactation: Excretion of the drug in breast milk is present Â
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: nalbuphineÂ
Pronounced: NAL-bue-feenÂ
Why do we use nalbuphine?Â
It is used to manage pain, as an analgesic before and after surgery, and during labor and delivery.Â